https://www.selleckchem.com/products/gossypol.html
RASi prescription was associated with a lower risk of kidney failure or death (HR 0.79, 95% CI 0.66, 0.95), an association not modified by age (P for interaction= .72). It was not significantly associated with cardiovascular events. During the first 3years of follow-up, 14% of patients were hospitalized with AKI or hyperkalemia, but risk was not higher among those prescribed RASi's (HR 0.75, 95% CI 0.55-1.02) and age did not modify its effect (P for interaction= .28). This study shows that aging does not appear to modify either RASi's